Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre

S. Dolli, B. Russell, C.L. Moss, E. Tsiota, C. Gousis, J. Roca, A. Sita-Lumsden, M. Khan, D. Joshi, K. Zakli, D. Smith, V. Michalarepa, R. Krietelet, D. Enting, L. Flanders, M. Lei, E. Sawyer, J. Spicer, P. Ross, A. Montes, M. Van Hemelrijck

1Guy’s Cancer, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Comprehensive Cancer Centre, KCL - King’s College London, London, UK; 3Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 4Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 5Translational Urology Research, King’s College London, London, UK

Background: Early reports in the COVID-19 pandemic suggested higher mortality for cancer patients. The impact of potentially immunosuppressive systemic anti-cancer treatments (SACT) was unknown. This study analysed the delivery of SACT for patients with solid malignancies during the COVID-19 outbreak in 2020 compared to the same period in 2019 to inform future clinical decision-making.

Methods: All patients receiving at least one SACT at Guy’s comprehensive Cancer Centre during the COVID-19 outbreak for solid tumours (1st March–31st May 2020) were compared to the same period in 2019. SARS-CoV2 infection was by positive RT-PCR test. Data collected: demographics, tumour type/stage and treatment (chemotherapy, immunotherapy (IO), biological-targeted (BT)).

Results: 2125 patients received SACT in 2020, compared to 2450 in 2019 (13% decrease). Demographics were comparable with mean age of 62.56% females in 2020 vs 54% in 2019, 85% vs 83% in the low socio-economic category, 63% vs 73% PS 0-1; 30% vs 29% uro-gynaecological, 27% vs 24% breast and 20% vs 23% GI tumours. In 2020 compared to 2019, there was an increase in metastatic disease (71% vs 62%), decrease in IO (34% vs 42%), increase in IO (10% vs 6%), but similar rates of SACT (38% vs 37%). Treatment paradigms were similar in 2020 and 2019: neoadjuvant (28% vs 29%), radical (4% vs 5%) and palliative (69% vs 67%). Earlier palliative treatments were prioritised in 2020 with significant increase in treatments in 1st line (72% vs 67%; p<0.02) and reduction in 2nd line (12% vs 27%; p<0.05). 42 of 2125 patients (2%) developed SARS-CoV2 infections; 38 GI, 26% breast with 69% on CT. Of 42 patients with COVID-19, 24 (57%) had severe infections and 6 (14%) resulted in COVID-related death.

Conclusions: These data suggest that SACT does not put solid tumour patients at much a higher additional risk from COVID-19. Despite a 13% decline in treatment rates, radical and early palliative treatment were prioritised. There was a low frequency (2%) of SARS-CoV-2 infection; comparable to the 1.4% point prevalence rate in our cancer population. However, this was during national lockdown with limited COVID-19 testing. The next steps are to evaluate the impact of new variant strains and COVID vaccination programme.

Legal entity responsible for the study: Guy’s Real-World Evidence.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.1601

1610P Delivery of ONCOlogic care at HOME: Ready for “ONCOHOME”

M. Ratti1, G. Procopio2, V. Guadalupe3, G. Grizzi2, M. Bonomi2, J. Saleni2, A. Gobbi3, R. Marchi1, G. Pogliacomi4, G. Donati4, M. Nazzari2, N. Bacciocchini5, M. Briganti6, B. Perrucchini3, M.O. Giganti7, S. Panni3, M. Donini1, A. Curti7, V. Gregorc3, R. Passalacqua1

1Oncology Department, ASST Cremona - Azienda Socio-Sanitaria Territoriale, Cremona, Italy; 2Oncology Department, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy; 3Oncology Department, IRCCS Ospedale San Raffaele, Milan, Italy

Background: During COVID pandemic, many cancer patients (pts) refused to come to hospital, suspending therapies, with ominous consequences. Based on positive (+) results of DOMONCOVIC, our homecare project for COVID+ cancer pts, we created a new model of assistance, ONCOHOME, delivering cancer care at home to immune-compromised pts. We aim to provide data on feasibility, efficacy and costs of this innovative model.

Methods: ONCOHOME is a multicenter project involving 3 Cancer Center (CC) of the North of Italy: National Cancer Institute, San Raffaele in Milan and Cremona CC. We created an organizational homecare model based on a medical and nursing team with a car equipped for home visits and a secretariat managing patient calls, with a dedicated phone number. The team administers cancer care at home and provides pts with the same assistance usually delivered in hospital. Patient-reported outcome (PRO) assessment is performed.

Results: From August 3rd 2020 to May 5th 2021, 79 cancer pts were assisted at home by Cremona team, receiving oral (62 pts), subcutaneous (10pts) or intravenous therapy (7 pts). All types of cancer were included. 77% of pts had a metastatic disease, 88% had a PS ECOG 0-1. Median duration of assistance was 126 days (range 2-270 days). Most of the pts received oral chemotherapy (41pts). TKIs (25 pts), hormonal therapy (12 pts), supportive care with denosumab and zolendronic acid (5 pts) and immunotherapy (1 patient, pt) were successfully administered at home, too. 13 pts required hospitalization due to clinical complications. In this group, only 2 pts were admitted to hospital due to severe toxicity; in particular, 1 pt treated with trifluridin/tipiracil developed febrile neutropenia and 1 pt treated with gefitinib reported Grade 3 diarrhea. Both pts were discharged and continued to be assisted at home.

Conclusions: ONCOHOME showed that inpatient or outpatient cancer drug administration could be successfully replaced by home administration, for appropriate therapies and selected pts. This model is feasible at an affordable cost. The project is ongoing, planning to accrue other 100 pts for each center. ONCOHOME will be implemented with electronic devices for PRO evaluation, certified telemedicine service and non-invasive wearable smart tissue monitoring physiological parameters devices.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.1602

1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study

R. Berardi1, G. Mentrstai, S. Crocetti1, N. La Verde3, R. Chari1, M.S. Cona1, L. Nicolaidi2, C. De Filippis1, S. Oldani1, F. Pecci1, F. Venanzi1, M.B.L. Rocchi3, A. Savini1, L. Cantini1, M. Pistelli1

1Oncology Clinic, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy; 2Medical Oncology Department, ASST Fatebenefratelli Sacco, Milan, Italy; 3Oncology Clinic, ULSS6 Ospedali Riuniti Padova Sud, Padua, Italy; 4Biomolecular Sciences, Service of Biostatistics, University of Urbino “Carlo Bo”, Urbino, Italy

Background: The coronavirus disease (COVID-19) has profoundly impacted on cancer care since March 2020. With our country in the eye of the pandemic storm, much a higher additional risk from COVID-19. Despite a 13% decline in treatment rates, radical and early palliative treatment were prioritised. There was a low frequency (2%) of SARS-CoV-2 infection; comparable to the 1.4% point prevalence rate in our cancer population. However, this was during national lockdown with limited COVID-19 testing. The next steps are to evaluate the impact of new variant strains and COVID vaccination programme.

Conclusions: These data suggest that SACT does not put solid tumour patients at much a higher additional risk from COVID-19. Despite a 13% decline in treatment rates, radical and early palliative treatment were prioritised. There was a low frequency (2%) of SARS-CoV-2 infection; comparable to the 1.4% point prevalence rate in our cancer population. However, this was during national lockdown with limited COVID-19 testing. The next steps are to evaluate the impact of new variant strains and COVID vaccination programme.

Legal entity responsible for the study: Guy’s Real-World Evidence.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2021.08.1601